Basic and clinical studies of the combined multi-targeting therapy of leukemia
10.3760/cma.j.issn.1009-9921.2008.06.001
- VernacularTitle:白血病多靶点联合治疗的基础和临床研究
- Author:
Jifang ZHOU
;
Saijuan CHEN
- Publication Type:Journal Article
- Keywords:
Leukemia;
Target therapy;
Tretinoin;
Arsenicals;
Rubescensine
- From:
Journal of Leukemia & Lymphoma
2008;17(6):401-403,414
- CountryChina
- Language:Chinese
-
Abstract:
The success of ATRA and ATO in APL treatment furuishes the first model of molecular target-based induction of differentiation and apoptosis.Two drugs all target PML-RARα oncoprotein through different moieties and induce APL cells differentiation and apoptosis.In acute myeloid leukemia M2b,we reveal that gain-of-function of C-kit coexists with persistent AML1-ETO,suggesting that abnormal C-kit may serve as a therapeutic target in AML L-M2b Oridonin becomes a potential candidate target drug which specifically degrades AML1-ETO protein. Experiment in vitro proves the combinatorial effectiveness of imatinib and cytarabin in the treatment of chronic myelogenous leukemia(CML).Imatinib is an inhibitor of abnormal protein tyrosine kinases activity. While arsenic agent triggers the degradation of bcr-abl, and combination of the two drugs in treating CML leads to a better outcome.
